Iberdomide show promising efficacy in heavily pretreated patients with Relapsed/Refractory Multiple Myeloma
Iberdomide, an oral, novel cereblon E3 ligase modulator, showed a manageable safety profile and promising efficacy in combination with dexamethasone and daratumumab, bortezomib or carfilzomib in patient with relapsed/refractory multiple myeloma. In this MEDtalk Sagar Lonial, Professor at the Department of Hematology and Medical Oncology, Emory University, presents the data and answer some questions from Agoston Gyula Szabo, MD at Department of Hematology, Rigshospitalet, Copenhagen.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.